SCHEMBL378297

SCHEMBL378297

COc1cc(O)cc(C=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 5/20 0.58
CYP1B1 Q16678 5/20 0.58
PTGS2 P35354 3/20 0.58
TTR P02766 2/20 0.58
ALOX5 P09917 2/20 0.58
BACE1 P56817 1/20 0.58
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 3/20 0.56
MEN1 O00255 3/20 0.56
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
CYP3A4 P08684 2/20 0.56
HPGD P15428 2/20 0.56
USP2 O75604 1/20 0.56
TP53 P04637 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ERN1 O75460 2/20 0.53
ABL1 P00519 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29958196 1.00 CYP1A1 (0.58) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL228003 0.86 CYP1A1 (0.64) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL1663786 0.86 ALDH1A1 (0.58) CYP1A1CYP1B1PTGS2TTRALOX5
Water SCHEMBL28227114 0.84 CYP1A1 (0.61) CYP1A1CYP1B1PTGS2TTRALOX5
Formic Acid Methyl Ester SCHEMBL28071788 0.80 CYP1A1 (0.56) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL19359679 0.80 CYP1A1 (0.77) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL11931426 0.80 NPC1 (0.69) CYP1A1ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL26908513 0.79 BACE1 (0.42) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL9928608 0.78 CYP1A1 (0.58) CYP1A1CYP1B1PTGS2TTRALOX5
SCHEMBL29951799 0.78 ALDH1A1 (0.50) CYP1A1CYP1B1PTGS2TTRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260002924-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-01 US claimed
US-20250049831-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND GE, XIN (CN) 2025-02-13 US claimed
EP-4477693-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS Korea Research Institute of Chemical Technology (KR) 2024-12-18 EP claimed
EP-4442262-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND Ge, Xin (CN) 2024-10-09 EP claimed
WO-2023195794-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS 한국화학연구원 2023-10-12 WO claimed
WO-2023098650-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND 盖鑫 2023-06-08 WO claimed
CN-116196321-A Application and preparation of bisepoxylignanoid compound and antiviral composition 盖鑫 2023-06-02 CN claimed
US-20230148641-A1 FLAVOR COMPOSITION FIRMENICH SA (CH) 2023-05-18 US claimed
EP-4125427-A1 FLAVOR COMPOSITION Firmenich SA (CH) 2023-02-08 EP claimed
CN-115279206-A Flavor composition 弗门尼舍有限公司 2022-11-01 CN claimed
WO-2021198199-A1 FLAVOR COMPOSITION FIRMENICH SA (CH) 2021-10-07 WO claimed
US-10751330-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-25 US claimed
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-05-14 US claimed
US-10092550-B2 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof IONS PHARMACEUTICAL S.À R.L. (LU) 2018-10-09 US claimed
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-04-20 US claimed
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US claimed
EP-4737508-A1 CHEMICAL RECYCLING METHOD FOR MIXED WASTE POLYMERS Korea Research Institute of Chemical Technology (KR) 2026-05-06 EP disclosed
US-20260002924-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-01 US disclosed
US-4133729-A Production of 1,2-bis(hydroxy-phenyl)ethane-1,2-diols by electrolytic reduction MONSANTO COMPANY (US) 1979-01-09 US disclosed
US-4087336-A Electrolytic reductive coupling of hydroxybenzaldehydes MONSANTO COMPANY (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260002924-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS FGB, NR4A1, CYP2E1 CYP1A1 35/4885CYP1B1 19/4885PTGS2 782/4885
US-10751330-B2 Human therapeutic agents INMT, HNMT, HASPIN CYP1A1 2202/4885CYP1B1 3037/4885PTGS2 2234/4885
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, CPT1A CYP1A1 1680/4885CYP1B1 1687/4885PTGS2 2108/4885
US-20250049831-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND ACE2, LBR, YWHAZ CYP1A1 1012/4885CYP1B1 1371/4885PTGS2 621/4885
US-10092550-B2 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof INMT, HNMT, CPT1A CYP1A1 1680/4885CYP1B1 1687/4885PTGS2 2108/4885
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT CYP1A1 1827/4885CYP1B1 1866/4885PTGS2 2709/4885
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN CYP1A1 2202/4885CYP1B1 3037/4885PTGS2 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.